AzTrials
AzTrials

The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic StabilityPhase 4NCT05948267

The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults.

A Phase 4 study testing ketamine- dexmeditomidine admixure and Propofol, Lidocaine and fentanyl in people with The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability, run by Kasr El Aini Hospital at 2 sites in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of our study to compare two different doses of Dexmedetomidine added to anesthetic dose of ketamine in the induction of general anesthesia in adult patients regarding the hemodynamic profile, adequacy of hypnosis, intubation conditions and recovery type. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
ketamine- dexmeditomidine admixure and Propofol, Lidocaine and fentanyl
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
2 sitesEgypt
Study dates
25 May 2023to 15 Nov 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All patients undergoing elective general surgery. Patients aged >18 years. ASA I and II. Both sexes.

Who cannot join

  • All patients undergoing emergency surgery. Patients less than 18 years. History of difficult intubation, abnormal airway examination Cardiac morbidities (impaired contractility with ejection fraction < 50%, heart block, arrhythmias, tight valvular lesions).
  • Patients on angiotensin converting enzyme inhibitors and angiotensin receptor blockers medications.
  • Patients with uncontrolled hypertension. Patients with allergy of any of the study drugs. Body mass index > 35 kg/m2

Trial locations and contacts

2 sites in 1 country.

Egypt2 sites
  • Kasr Al Ainy Hospitals

    Cairo

  • Kasr Alainy Hospitals Cairouniversity

    Cairo

Other trials in Egypt

About this study

Official title: The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability During Anesthesia Induction in Adults: A Randomized Controlled Comparison of Two Doses

The aim of our study to compare two different doses of Dexmedetomidine added to anesthetic dose of ketamine in the induction of general anesthesia in adult patients regarding the hemodynamic profile, adequacy of hypnosis, intubation conditions and recovery type.

We hypothesize that the use of Ketodex during induction of general anesthesia will produce better control regarding the hemodynamic profiles and quality of intubation than propofol.

Read the detailed description

A randomized, double-blinded, controlled trial. All adult patients (ASA I and II), aged > 18 years old undergoing elective general surgery and meeting the inclusion criteria will be included in the study.

The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.

In the operating room; Baseline preoperative arterial pressures (systolic, mean\& diastolic) will be the mean of 3 consecutive readings with 30 seconds apart, recorded in the supine position. HR and oxygen saturation baseline will also be recorded.

drug preparation: Propofol (P) group: Propofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes.

Ketamine-Dexmedetomidine (KD5) group: ketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes.

Ketamine-Dexmedetomidine (KD3) group: ketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes.

induction of anesthesia: After 3-minutes of preoxygenation, the patients in each group will receive a dose of 0.1ml/Kg boluses of the drugs preparations until achieving clinical loss of consciousness (defined as no response to auditory command and the disappearance of a patient's eyelash reflex).

After loss of consciousness, atracurium 0.5 mg/kg will be administered over 5 seconds, and tracheal intubation will be done after 3 minutes of ventilation through direct laryngoscopy.

The intubation conditions will be graded by the same anesthetist who performed intubation as excellent, good, or poor.

When the trachea is intubated, mechanical ventilation will be applied to obtain SpO2 > 95% and end-tidal CO2 between 30-40 mmHg, and anesthesia will be maintained by 1% isoflurane in air/oxygen admixture. Atracurium maintenance dose of 10 mg will be administered every 20 minutes for maintenance of muscle relaxation.

Any incidence of hypotension (defined as MBP <65 mmHg) will be recorded 20 min after induction. Any episode of hypotension (mean arterial <65 mmHg) will be managed by incremental doses of intravenous ephedrine 5 mg (which will be repeated if hypotension persists for 2 minutes).

Hypertension and tachycardia are defined as mean arterial pressure or heart rate >20% of baseline, respectively. Persistent hypertension (blood pressure increasing after one measurement) will be managed by intravenous 0.25 mg/kg propofol in all groups. Bradycardia (heart rate < 50 bpm) will be managed by 0.5 mg of intravenous atropine.

  1. post-operative : After recovery of the patient we will record the Incidence of emergence agitation, Recovery time, the modified Alderet score system for postoperative recovery and the incidence of Postoperative Complications (nausea \&vomiting).

The total modified Aldrete score values range from 0 to 12. Scores closer to 0 indicate that the patient is closest to the anesthesia state , Scores of 9 and above indicate that the patient can be discharged and the closer the score is to 12, the higher the chances for all anesthetic, regardless of administering method, to have worn off.

Study outcomes:

  1. Primary outcome: Incidence of post-induction hypotension defined as a mean arterial pressure MAP < 65 mmHg and/or≤ 70% of baseline reading for > 10 s within the first 20 min after general anesthesia induction.
  2. Secondary outcome:

Mean arterial pressure, SBP, DBP, heart rate at baseline, immediately after induction, after intubation, then every 2-minute till skin incision.

Total Ephedrine requirements during the period from induction anesthesia to skin incision.

Total Atropine requirements during the period from induction anesthesia to skin incision.

Severe post-induction hypotension (mean arterial pressure ≤60 mmHg), hypertension, bradycardia, and tachycardia during 30 min from induction anesthesia.

The Number of hypotensive episodes. Intubation time (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation) Response to intubation score. Total dexmedetomidine, ketamine and propofol dose per weight. Recovery time Incidence of emergence agitation using Riker Sedation-Agitation Scale

Statistical analysis:

Sample size justification The incidence of post induction hypotension in a previous study (10) for the control group was 58%. At alpha error of 0.05, we calculated that 96 patients would give 80% power to detect 30% absolute reduction in the incidence of hypotension in the treatment group. However, to allow the comparisons between the control group and each treatment group, an adjusted P (Bonferroni correction) of 0.025 was set for the primary outcome and the required sample size increased to 114 patients (38 patients per group). The number of prepared envelopes will be 123 (41 envelopes per group) to compensate for possible dropouts. The sample size was calculated using MedCalc Software version 14 (MedCalc Software bvba, Ostend, Belgium).

Statistical methods The collected data will be coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 22.0, IBM Corp., Chicago, USA, 2013. Quantitative data will be described as mean±SD (standard deviation) and then compared using an independent t-test. Qualitative data will be described as numbers and percentages and compared using the Chi-square test. The level of significance will be taken at p-value < 0.050 is significant, otherwise is non-significant.

Being tested
ketamine- dexmeditomidine admixure, Propofol, Lidocaine and fentanyl
Keywords
ketamine-dexmeditomedine mixture, ketodex, general anesthesia, hemodynamic stability, anesthesia induction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ketamine- dexmeditomidine admixureDrug

    ketamine in anesthetic dose mixed with two different doses of dexmeditomidine

  • Propofol, Lidocaine and fentanylDrug

    Propofol (2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml

Study groups in NCT05948267
Study groupRoleWhat they receive
Propofol (P) groupActive comparatorPropofol(2mg/kg) prepared as will be mixed with 2 mL Lidocaine (40 mg) for concentration 10mg/ml and fentanyl (1mic/kg) prepared for concentration 10mg/ml in 2 separate syringes.
Receives: Drug: Propofol, Lidocaine and fentanyl
Ketamine-Dexmedetomidine (KD5) groupActive comparatorketamine (1mg/kg) prepared for concentration 10mg/ml, Dexmedetomidine (0.5microg/kg slow IV) prepared for concentration of 5mic /ml in 2 separate syringes.
Receives: Drug: ketamine- dexmeditomidine admixure
Ketamine-Dexmedetomidine (KD3) groupActive comparatorketamine (1mg/kg) prepared concentration 10mg/ml, Dexmedetomidine (0.3microg/kg slow IV) prepared for concentration of 3mic /ml in 2 separate syringes.
Receives: Drug: ketamine- dexmeditomidine admixure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of post-induction hypotension

    mean arterial pressure MAP < 65 mmHg and/or≤ 70% of baseline reading for > 10 s

    Measured: the first 20 min after general anaesthesia induction.

Secondary outcomes (9)
  1. Total Ephedrine requirements

    Measured: during the period from induction anesthesia to skin incision. maximum 30 minutes

  2. Total Atropine requirements

    Measured: during the period from induction anesthesia to skin incision. max 30 minutes

  3. Severe post-induction hypotension (mean arterial pressure ≤60 mmHg), hypertension, bradycardia, and tachycardia

    Measured: during 30 min from induction anesthesia.

  4. The Number of hypotensive episodes

    Measured: the 2 hours procedure

  5. Intubation time (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation)

    (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation) (time from insertion of the laryngoscope into the mouth until its removal after tracheal intubation)

    Measured: maximum 5 minutes

  6. Response to intubation score.

    Measured: maximum 5 minutes

  7. Total dexmedetomidine, ketamine and propofol dose per weight.

    Measured: the whole procedure . 2 hours

  8. Recovery time

    Measured: less than 15 minutes

  9. Incidence of emergence agitation using Riker Sedation-Agitation Scale

    Measured: 60 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Jul 2023
  2. Study start25 May 2023
  3. Primary completion30 Oct 2023
  4. Study completion15 Nov 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Other
Allocation
Randomised
Intervention model
Parallel groups
Model description
The patients will be divided into 3 equal groups: Propofol group (p), Ketamine-Dexmedetomidine (KD5) group and Ketamine-Dexmedetomidine (KD3) group.
Masking
Single blind
Who is masked
Participant
Enrolment
120 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05948267
Sponsor's protocol ID
MS-94-2023
Status last verified
Jan 2025
First submitted
15 Jun 2023
Last updated
16 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing ketamine- dexmeditomidine admixure and Propofol, Lidocaine and fentanyl in people with The Effect of Ketamine - Dexmedetomidine Admixture (Ketodex) on Hemodynamic Stability, run by Kasr El Aini Hospital at 2 sites in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of post-induction hypotension (time frame: the first 20 min after general anaesthesia induction.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in